minute/1.73m2, respectively). CONCLUSION: This analysis identified a significant decrease in GFR over time. Persons with controlled BP taking antihypertensive therapy had higher GFR than those taking no medication suggesting that antihypertensive medication use preserves kidney function.
Idrovo J 1 , Rivas R 2 , Zapata L 2 1 Guia Mark, Mexico, DF, Mexico, 2 Guia Mark, México, DF, Mexico OBJECTIVE: The treatment of chronic kidney disease (CKD) with dialysis is associated with the appearance of hyperphosphatemia, which contributes to the presence of vascular calcifications, thus increasing the probability of the occurrence of cardiovascular events and death in these patients. The objective of this analysis was to evaluate the incremental costeffectiveness of the use of sevelamer to manage hyperphosphatemia secondary to CKD from an institutional perspective. METHODS: A Markov model was created in TreeAge to estimate the costs and benefits of the treatment with sevelamer or calcium tablets in patients with renal failure considering a temporary horizon of 60 months. The transition probabilities were taken from clinical trials identified through a systematic review of literature. The effectiveness measure considered was an increase in patient survival. Data related to the use of resources were obtained from a nominal group and cost information was obtained from price lists and rates published by health institutions. In addition a univariate sensitivity analysis was performed on the probability of death for sevelamer group. Costs were estimated using 2007 prices and are expressed in US dollars (exchange rate of 10.93 pesos per US dollar). Research Centre on the Portuguese Economy-CISEP, Lisboa, Portugal OBJECTIVE: To determine the incremental cost-effectiveness ratio (ICER) of cinacalcet as an adjuvant therapy for SHPT from the perspective of the Portuguese NHS. METHODS: A probabilistic Markov model was used to compare best standard care (BSC) with BSC plus cinacalcet. The model was developed in cycles of six months until the death of all patients. Patients were distributed according to the risk of hospital admission due to cardiovascular events, major or minor fractures and parathyroidectomies. The absence of events and/or death was also considered. The probabilities of SHPT's complications were obtained from the literature. Portuguese official mortality rates were weighted by the presence of renal insufficiency and by the PTH levels. Due to lack of alternative, the resources used (only direct medical costs) were estimated by a Delphi panel of eight nephrologists and by a physical medicine and rehabilitation specialist. Unit costs were obtained from Portuguese official sources. Market shares of medicines prescribed in outpatient services were selected from the IMS. RESULTS: Cinacalcet increases 0.4 life years (LY) per patient with SHPT. The use of cinacalcet saves hospital admissions and follow-up costs of secondary events, but is associated with an ICER of €53,682 per LY gained. However, if dialysis costs are not considered, the ICER is €32,374 per LY gained and the probability of being cost-effective increases from 61% to 83% if acceptability for reimbursement is limited at €50.000 per LY gained. CONCLU-SION: Using a €50,000 WTP threshold, cinacalcet was found cost-effective if the increased cost of dialysis was excluded. The inclusion of this cost (induced by a longer life expectancy) leads to an ICER of €53,682 per LY gained. A clear paradox arises here as the alternative becomes less cost-effective by increasing dialysis patients' longevity. Abstracts A301
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